Evolocumab
MCE 国际站：Evolocumab
CAS：1256937-27-5
品牌：MedChemExpress (MCE)
存储条件：Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性：Evolocumab (AMG 145) 是一种人单克隆抗体，可抑制 PCSK9。 Evolocumab 与循环的 PCSK9 蛋白结合，抑制其与 LDLR 结合。 Evolocumab可用于高胆固醇血症和动脉粥样硬化性心血管疾病的研究[1]。 IC50 和目标：PCSK9[1]
热销产品：5-Propargylamino-dCTP | Lirentelimab | Revdofilimab | YS-370 | Gosuranemab | Homoeriodictyol | BRD7552 | Canthaxanthin | γ-Cyclodextrin | YTHDF2, Human (His)
研究领域：Metabolic Enzyme/Protease
作用靶点：Ser/Thr Protease
热门产品线：重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物 | 寡核苷酸
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides
参考文献：
[1]. Fala L, et, al. Repatha (Evolocumab): Second PCSK9 Inhibitor Approved by the FDA for Patients with Familial Hypercholesterolemia. Am Health Drug Benefits. 2016 Mar;9(Spec Feature):136-9.